A
Atsushi Imaizumi
Researcher at University of Shizuoka
Publications - 29
Citations - 1810
Atsushi Imaizumi is an academic researcher from University of Shizuoka. The author has contributed to research in topics: Curcumin & Medicine. The author has an hindex of 16, co-authored 27 publications receiving 1476 citations.
Papers
More filters
Journal ArticleDOI
Innovative preparation of curcumin for improved oral bioavailability.
Hiroki Sasaki,Yoichi Sunagawa,Yoichi Sunagawa,Kenji Takahashi,Atsushi Imaizumi,Hiroyuki Fukuda,Tadashi Hashimoto,Hiromichi Wada,Yasufumi Katanasaka,Hideaki Kakeya,Masatoshi Fujita,Koji Hasegawa,Tatsuya Morimoto +12 more
TL;DR: THERACURMIN exhibited an inhibitory action against alcohol intoxication after drinking in humans, as evidenced by the reduced acetaldehyde concentration of the blood, and shows a much higher bioavailability than currently available preparations.
Journal ArticleDOI
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
Masashi Kanai,Kenichi Yoshimura,Masanori Asada,Atsushi Imaizumi,Chihiro Suzuki,Shigemi Matsumoto,Takafumi Nishimura,Yukiko Mori,Toshihiko Masui,Yoshiya Kawaguchi,Kazuhiro Yanagihara,Shujiro Yazumi,Tsutomu Chiba,Sushovan Guha,Bharat B. Aggarwal +14 more
TL;DR: Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.
Journal ArticleDOI
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
Masashi Kanai,Atsushi Imaizumi,Yoshihiko Otsuka,Hiroki Sasaki,Momo Hashiguchi,Kazu Tsujiko,Shigemi Matsumoto,Hiroshi Ishiguro,Tsutomu Chiba +8 more
TL;DR: THERACURMIN can safely increase plasma curcumin levels in a dose-dependent manner at least up to 210 mg without saturating the absorption system, and is the first nanoparticle formulation ofCurcumin that demonstrates improved bioavailability in human subjects.
Journal ArticleDOI
A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
Masashi Kanai,Yoshihiko Otsuka,Kazunori Otsuka,Maremi Sato,Takafumi Nishimura,Yukiko Mori,Michiya Kawaguchi,Etsuro Hatano,Yuzo Kodama,Shigemi Matsumoto,Yoshiki Murakami,Atsushi Imaizumi,Tsutomu Chiba,Jun Nishihira,Hiroyuki Shibata +14 more
TL;DR: Repetitive systemic exposure to high concentrations of curcumin achieved by Theracurmin® did not increase the incidence of adverse events in cancer patients receiving gemcitabine-based chemotherapy.
Journal ArticleDOI
Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study
Yasuaki Nakagawa,Shogo Mukai,Shigeru Yamada,Masayuki Matsuoka,Eri Tarumi,Tadashi Hashimoto,Chieko Tamura,Atsushi Imaizumi,Jun Nishihira,Takashi Nakamura +9 more
TL;DR: At 8 weeks after treatment initiation, knee pain VAS scores were significantly lower in the Theracurmin group than in the placebo group, except in the patients with initial VAS Scores of 0.15 or less, which shows modest potential for the treatment of human knee osteoarthritis.